ABSTRACT
Papillomaviruses are a large and diverse group of viruses. It includes approximately 200 fully described types that have been detected in humans. Human papilloma viruses (HPV) are etiologic agents during various, benign and malignant lesions of mucous membrane and skin epithelium. Very importantly, persistent HPV infection of certain types is a leading cause of carcinoma of uterine cervix, penis, vulva; vagina, anal canal and fauces (including tongue base and tonsils). HPV infection prophylaxis is the best means to control HPV-conditioned diseases, and vaccination, as had been demonstrated, --the most effective method of its prophylaxis. In this paper principle characteristics and clinical manifestations of papillomavirus infection, as well as effectiveness of vaccination against HPV are examined.
Subject(s)
Anus Neoplasms/prevention & control , Papillomaviridae/pathogenicity , Papillomavirus Infections/prevention & control , Penile Neoplasms/prevention & control , Tongue Neoplasms/prevention & control , Uterine Cervical Neoplasms/prevention & control , Anus Neoplasms/pathology , Anus Neoplasms/virology , Epithelial Cells/pathology , Epithelial Cells/virology , Female , Humans , Male , Mucous Membrane/pathology , Mucous Membrane/virology , Papillomaviridae/classification , Papillomaviridae/immunology , Papillomavirus Infections/pathology , Papillomavirus Infections/virology , Papillomavirus Vaccines/administration & dosage , Papillomavirus Vaccines/immunology , Penile Neoplasms/pathology , Penile Neoplasms/virology , Skin/pathology , Skin/virology , Tongue Neoplasms/pathology , Tongue Neoplasms/virology , Uterine Cervical Neoplasms/pathology , Uterine Cervical Neoplasms/virology , VaccinationABSTRACT
Natural killer cell activity (NK) in parallel with the interferon (IFN)-alpha and IFN-gamma production as well as with a level of IFN in the blood serum were studied in 15 patients with relapsing herpes genitalis (RHG). Rhidostin, well known as an IFN-alpha inducer, was used in a dose of 2 mg once daily for 3 days subcutaneously up to a total dose of 8 mg of the preparation. The NK cell activity and IFN-alpha production were shown to decrease in RHG more significantly in the stage of remission than during the relapse of the process. As a result of rhidostin therapy the NK cell activity was restored simultaneously with the positive clinical effect of the drug. Rhidostin was found to be an efficient modifier of the IFN system functioning in patients with RHG. The above data allow a conclusion that rhidostin exhibiting an independent antiviral and immunostimulating action might be useful in patients with a remission of RHG for prevention of its relapses.
